Clinical bottom line
Liquid biopsy technologies analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in plasma and urine offer promising, minimally invasive tools for monitoring urothelial carcinoma progression. Recent advances integrating multi-targeted urinary tumor DNA capture with machine learning algorithms have improved detection sensitivity and specificity. These approaches may complement or partially replace invasive cystoscopic surveillance, enabling earlier detection of recurrence and treatment resistance. However, standardization and validation in larger cohorts remain necessary before routine clinical implementation (Tang et al., 2026; Chaux et al., 2026).
What the evidence shows
Tang et al. (2026) conducted a multicenter prospective study employing multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma. Their approach demonstrated high accuracy in identifying disease presence and progression, outperforming traditional cytology and single-marker assays.
Chaux et al. (2026) review the role of liquid biopsy in genitourinary cancers, emphasizing ctDNA’s utility as a predictive biomarker for treatment selection and resistance monitoring in urothelial carcinoma. They highlight its potential to guide personalized therapy by capturing tumor heterogeneity non-invasively.
Albers Acosta et al. (2025) discuss integrating advanced imaging with biomarker-based liquid biopsy, underscoring the complementary nature of these modalities in comprehensive disease monitoring.
Homayoun et al. (2026) optimized diagnostic thresholds for a keratin 17–based urine liquid biopsy assay, improving detection in patients presenting with hematuria, a common urothelial carcinoma symptom.
Arévalo et al. (2023) describe optimized isolation techniques for CTCs and tumor hybrid cells (THCs) from blood samples, facilitating real-time monitoring of tumor dynamics in urothelial carcinoma patients.
Zhang et al. (2025) report on next-generation sequencing (NGS)-based plasma and urine ctDNA profiling for longitudinal monitoring of bladder carcinoma in situ, demonstrating feasibility and correlation with clinical outcomes.
Li et al. (2026) review multiple urinary biomarkers’ research progress, highlighting their non-invasive diagnostic and prognostic potential in urothelial carcinoma.
Caveats and uncertainty
Most studies are early-phase or observational, with limited large-scale validation.
Heterogeneity in assay platforms, target genes, and bioinformatics pipelines complicates cross-study comparisons.
Sensitivity may be reduced in low tumor burden or upper tract disease.
Standardized protocols and thresholds for clinical decision-making are lacking.
Cost-effectiveness and reimbursement issues remain to be addressed.
Integration with existing surveillance protocols requires further clinical trials.
How this may change practice
Liquid biopsy could reduce reliance on invasive cystoscopy for surveillance, improving patient comfort and compliance.
Real-time molecular monitoring may enable earlier detection of recurrence and therapeutic resistance.
Personalized treatment adjustments guided by liquid biopsy biomarkers could improve outcomes.
Multimodal approaches combining imaging and liquid biopsy may enhance diagnostic accuracy.
Clinicians should stay informed about emerging assays and consider participation in validation studies.
Implementation will require multidisciplinary collaboration and infrastructure development.